E-mail a Wiley Online Library Link

Hagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, Partow Kebriaei, Elias Jabbour, Michael Rytting, Sergernne York, Farhad Ravandi, Rebecca Garris, Monica Kwari, Stefan Faderl, Jorge Cortes, Richard Champlin and Susan O'Brien Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia Cancer 119

Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28136

Inotuzumab single-agent therapy is highly active, safe, and convenient in refractory-relapsed acute lymphocytic leukemia. A weekly dose schedule appears to be equally effective and less toxic than a single-dose schedule.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

Choose captcha format: Image or Audio. Click here if you need help.